Emma Reeve

Emma Reeve


Emma Reeve is an accomplished biopharmaceutical executive with more than 30 years of global financial experience across pharmaceutical, medical device, and bio-pharma companies.

Most recently, Emma served as Chief Financial Officer of Constellation Pharmaceuticals, Inc., a development-stage oncology company, prior to its acquisition by MorphoSys AG in 2021. Emma led Constellation’s IPO in 2018.

Prior to Constellation, Emma acted as interim Chief Financial Officer and Corporate Controller of Parexel International, a global biopharmaceutical services company, where she was responsible for all aspects of finance, investor relations, procurement, and facilities. In this role, she led the finance aspects of a sell-side process which culminated in an agreement to take the company private in a $5 billion leveraged buy-out.

Earlier in her career, Emma served as Chief Financial Officer of both Inotek Pharmaceuticals and Aton Pharma. Additionally, she held senior finance and operational roles at Bristol Myers Squibb, Merck, and Novartis.

Emma is currently Chair of the Board of Editas Medicine and serves on the Board of PTC Therapeutics and Aadi Bioscience, all public biotechnology companies. In addition, she serves on the Board of Directors for Cardurion Pharma.

Emma holds a B.Sc. in computer science from Imperial College, University of London and is an associate of the Institute of Chartered Accountants in England & Wales.

Back to Team